


# Expected Submission Timeline<sup>(1)</sup>



(1) Excluding Phase 1  
 (2) Projects within a specified year are not arranged by submission timing  
 (3) Submission strategy for the U.S. under evaluation  
 (4) Also known as BIVV009  
 (5) Acid Sphingomyelinase Deficiency  
 (6) Autosomal Dominant Polycystic Kidney Disease

(7) Also known as MEDI8897  
 (8) Gaucher Related Parkinson's Disease  
 (\*\*\*) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products